These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31459022)

  • 21. In vitro forecasting of drugs that may interfere with codeine bioactivation.
    Dayer P; Desmeules J; Striberni R
    Eur J Drug Metab Pharmacokinet; 1992; 17(2):115-20. PubMed ID: 1425809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain.
    Radford H; Simpson KH; Rogerson S; Johnson MI
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31141989
    [No Abstract]   [Full Text] [Related]  

  • 23. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1.
    Mortimer O; Persson K; Ladona MG; Spalding D; Zanger UM; Meyer UA; Rane A
    Clin Pharmacol Ther; 1990 Jan; 47(1):27-35. PubMed ID: 2295216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the assessment of drug metabolism by assays of codeine and its main metabolites.
    Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
    Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of environmental and genetic factors on codeine analgesia.
    Desmeules J; Gascon MP; Dayer P; Magistris M
    Eur J Clin Pharmacol; 1991; 41(1):23-6. PubMed ID: 1782973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
    Susce MT; Murray-Carmichael E; de Leon J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity.
    Hedenmalm K; Sundgren M; Granberg K; Spigset O; Dahlqvist R
    Ther Drug Monit; 1997 Dec; 19(6):643-9. PubMed ID: 9421105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
    Yu A; Kneller BM; Rettie AE; Haining RL
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
    Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
    Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.
    Haritos VS; Ching MS; Ghabrial H; Gross AS; Taavitsainen P; Pelkonen O; Battaglia SE; Smallwood RA; Ahokas JT
    Pharmacogenetics; 1998 Oct; 8(5):423-32. PubMed ID: 9825834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?
    He YJ; Brockmöller J; Schmidt H; Roots I; Kirchheiner J
    J Anal Toxicol; 2008 Mar; 32(2):178-82. PubMed ID: 18334103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.
    Kathiramalainathan K; Kaplan HL; Romach MK; Busto UE; Li NY; Säwe J; Tyndale RF; Sellers EM
    J Clin Psychopharmacol; 2000 Aug; 20(4):435-44. PubMed ID: 10917405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
    Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
    Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of morphine and morphine glucuronide levels and cytochrome P450 isoenzyme 2D6 genotype in codeine-related deaths.
    Frost J; Helland A; Nordrum IS; Slørdal L
    Forensic Sci Int; 2012 Jul; 220(1-3):6-11. PubMed ID: 22285504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes.
    Zhang WY; Tu YB; Haining RL; Yu AM
    Drug Metab Dispos; 2009 Jan; 37(1):1-4. PubMed ID: 18838503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mimicking gene defects to treat drug dependence.
    Sellers EM; Tyndale RF
    Ann N Y Acad Sci; 2000; 909():233-46. PubMed ID: 10911933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
    Haufroid V; Hantson P
    Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.